BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24440681)

  • 1. The LRP1-independent mechanism of PAI-1-induced migration in CpG-ODN activated macrophages.
    Thapa B; Kim YH; Kwon HJ; Kim DS
    Int J Biochem Cell Biol; 2014 Apr; 49():17-25. PubMed ID: 24440681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel regulatory mechanism and functional implication of plasminogen activator inhibitor-1 (PAI-1) expression in CpG-ODN-stimulated macrophages.
    Thapa B; Kim YH; Kwon HJ; Kim DS
    Mol Immunol; 2012 Jan; 49(4):572-81. PubMed ID: 22078208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr⁹²⁵.
    Thapa B; Koo BH; Kim YH; Kwon HJ; Kim DS
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1696-701. PubMed ID: 25063025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAI-1 modulates cell migration in a LRP1-dependent manner via β-catenin and ERK1/2.
    Kozlova N; Jensen JK; Chi TF; Samoylenko A; Kietzmann T
    Thromb Haemost; 2015 May; 113(5):988-98. PubMed ID: 25694133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides induce expression of proinflammatory cytokines and chemokines in astrocytes: the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-kappaB activation.
    Lee S; Hong J; Choi SY; Oh SB; Park K; Kim JS; Karin M; Lee SJ
    J Neuroimmunol; 2004 Aug; 153(1-2):50-63. PubMed ID: 15265663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of Proliferation and Migration of Mouse Macrophages by Type B CpG-ODNs Is F-Spondin and IL-1Ra Dependent.
    Chen TA; Liao CC; Cheng YC; Chen YP; Hsu YF; Liang CM; Liang SM
    PLoS One; 2015; 10(6):e0128926. PubMed ID: 26042735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
    Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
    Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.
    Wu J; Strawn TL; Luo M; Wang L; Li R; Ren M; Xia J; Zhang Z; Ma W; Luo T; Lawrence DA; Fay WP
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):111-20. PubMed ID: 25378411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation.
    Lee JG; Lim EJ; Park DW; Lee SH; Kim JR; Baek SH
    Cell Signal; 2008 Dec; 20(12):2266-75. PubMed ID: 18817866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding.
    Molad Y; Pokroy-Shapira E; Carmon V
    Innate Immun; 2013 Dec; 19(6):623-30. PubMed ID: 23475790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression.
    Lim EJ; Lee SH; Lee JG; Kim JR; Yun SS; Baek SH; Lee C
    Exp Mol Med; 2007 Apr; 39(2):239-45. PubMed ID: 17464186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR; Church FC
    Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
    Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
    J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides.
    Brownlie R; Zhu J; Allan B; Mutwiri GK; Babiuk LA; Potter A; Griebel P
    Mol Immunol; 2009 Sep; 46(15):3163-70. PubMed ID: 19573927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.
    Suzuki K; Suda T; Naito T; Ide K; Chida K; Nakamura H
    Am J Respir Crit Care Med; 2005 Apr; 171(7):707-13. PubMed ID: 15640365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration.
    Ichimura A; Matsumoto S; Suzuki S; Dan T; Yamaki S; Sato Y; Kiyomoto H; Ishii N; Okada K; Matsuo O; Hou FF; Vaughan DE; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2013 May; 33(5):935-42. PubMed ID: 23471233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin induces the low density lipoprotein receptor-related protein 1 (LRP1) degradation by the proteasomal system in J774 macrophage-derived cells.
    Ceschin DG; Sánchez MC; Chiabrando GA
    J Cell Biochem; 2009 Feb; 106(3):372-80. PubMed ID: 19115269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
    Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
    J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.
    Luo M; Ji Y; Luo Y; Li R; Fay WP; Wu J
    J Thromb Haemost; 2017 Dec; 15(12):2451-2460. PubMed ID: 29028290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
    Li B; Zhang R; Li J; Zhang L; Ding G; Luo P; He S; Dong Y; Jiang W; Lu Y; Cao H; Zheng J; Zhou H
    Int Immunopharmacol; 2008 Mar; 8(3):379-89. PubMed ID: 18279792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.